By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Illumina has gone on the offensive against Roche's hostile bid for the San Diego-based company urging its shareholders to reject nominees put forth by Roche for Illumina's board of directors.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.
Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.
The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.
Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.